Cargando…
Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations
Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) were developed to overcome EGFR T790M-mediated resistance to first- and second-generation EGFR-TKIs. Third-generation EGFR-TKIs, such as osimertinib and nazartinib, are effective for patients with the EGF...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739653/ https://www.ncbi.nlm.nih.gov/pubmed/29285266 http://dx.doi.org/10.18632/oncotarget.22297 |
_version_ | 1783287907613671424 |
---|---|
author | Masuzawa, Keita Yasuda, Hiroyuki Hamamoto, Junko Nukaga, Shigenari Hirano, Toshiyuki Kawada, Ichiro Naoki, Katsuhiko Soejima, Kenzo Betsuyaku, Tomoko |
author_facet | Masuzawa, Keita Yasuda, Hiroyuki Hamamoto, Junko Nukaga, Shigenari Hirano, Toshiyuki Kawada, Ichiro Naoki, Katsuhiko Soejima, Kenzo Betsuyaku, Tomoko |
author_sort | Masuzawa, Keita |
collection | PubMed |
description | Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) were developed to overcome EGFR T790M-mediated resistance to first- and second-generation EGFR-TKIs. Third-generation EGFR-TKIs, such as osimertinib and nazartinib, are effective for patients with the EGFR T790M mutation. However, there are no direct comparison data to guide the selection of a third-generation EGFR-TKI for patients with different EGFR mutations. We previously established an in vitro model to estimate the therapeutic windows of EGFR-TKIs by comparing their relative efficacies against cells expressing mutant or wild type EGFRs. The present study used this approach to characterize the efficacy of third-generation EGFR-TKIs and compare them with that of other EGFR-TKIs. Treatment efficacy was examined using human lung cancer-derived cell lines and Ba/F3 cells, which were transduced with clinically relevant mutant EGFRs. Interestingly, mutation-related differences in EGFR-TKI sensitivity were observed. For classic EGFR mutations (exon 19 deletion and L858R, with or without T790M), osimertinib showed lower IC50 values and wider therapeutic windows than nazartinib. For less common EGFR mutations (G719S or L861Q), afatinib showed the lowest IC50 values. For G719S+T790M or L861Q+T790M, the IC50 values of osimertinib and nazartinib were around 100 nM, which was 10- to 100-fold higher than those for classic+T790M mutations. On the contrary, osimertinib and nazartinib showed similar efficacies in cells expressing EGFR exon 20 insertions. The findings highlight the diverse mutation-related sensitivity pattern of EGFR-TKIs. These data may help in the selection of EGFR-TKIs for non-small cell lung cancer patients harboring EGFR mutations. |
format | Online Article Text |
id | pubmed-5739653 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57396532017-12-28 Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations Masuzawa, Keita Yasuda, Hiroyuki Hamamoto, Junko Nukaga, Shigenari Hirano, Toshiyuki Kawada, Ichiro Naoki, Katsuhiko Soejima, Kenzo Betsuyaku, Tomoko Oncotarget Research Paper Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) were developed to overcome EGFR T790M-mediated resistance to first- and second-generation EGFR-TKIs. Third-generation EGFR-TKIs, such as osimertinib and nazartinib, are effective for patients with the EGFR T790M mutation. However, there are no direct comparison data to guide the selection of a third-generation EGFR-TKI for patients with different EGFR mutations. We previously established an in vitro model to estimate the therapeutic windows of EGFR-TKIs by comparing their relative efficacies against cells expressing mutant or wild type EGFRs. The present study used this approach to characterize the efficacy of third-generation EGFR-TKIs and compare them with that of other EGFR-TKIs. Treatment efficacy was examined using human lung cancer-derived cell lines and Ba/F3 cells, which were transduced with clinically relevant mutant EGFRs. Interestingly, mutation-related differences in EGFR-TKI sensitivity were observed. For classic EGFR mutations (exon 19 deletion and L858R, with or without T790M), osimertinib showed lower IC50 values and wider therapeutic windows than nazartinib. For less common EGFR mutations (G719S or L861Q), afatinib showed the lowest IC50 values. For G719S+T790M or L861Q+T790M, the IC50 values of osimertinib and nazartinib were around 100 nM, which was 10- to 100-fold higher than those for classic+T790M mutations. On the contrary, osimertinib and nazartinib showed similar efficacies in cells expressing EGFR exon 20 insertions. The findings highlight the diverse mutation-related sensitivity pattern of EGFR-TKIs. These data may help in the selection of EGFR-TKIs for non-small cell lung cancer patients harboring EGFR mutations. Impact Journals LLC 2017-11-06 /pmc/articles/PMC5739653/ /pubmed/29285266 http://dx.doi.org/10.18632/oncotarget.22297 Text en Copyright: © 2017 Masuzawa et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Masuzawa, Keita Yasuda, Hiroyuki Hamamoto, Junko Nukaga, Shigenari Hirano, Toshiyuki Kawada, Ichiro Naoki, Katsuhiko Soejima, Kenzo Betsuyaku, Tomoko Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations |
title | Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations |
title_full | Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations |
title_fullStr | Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations |
title_full_unstemmed | Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations |
title_short | Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations |
title_sort | characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739653/ https://www.ncbi.nlm.nih.gov/pubmed/29285266 http://dx.doi.org/10.18632/oncotarget.22297 |
work_keys_str_mv | AT masuzawakeita characterizationoftheefficaciesofosimertinibandnazartinibagainstcellsexpressingclinicallyrelevantepidermalgrowthfactorreceptormutations AT yasudahiroyuki characterizationoftheefficaciesofosimertinibandnazartinibagainstcellsexpressingclinicallyrelevantepidermalgrowthfactorreceptormutations AT hamamotojunko characterizationoftheefficaciesofosimertinibandnazartinibagainstcellsexpressingclinicallyrelevantepidermalgrowthfactorreceptormutations AT nukagashigenari characterizationoftheefficaciesofosimertinibandnazartinibagainstcellsexpressingclinicallyrelevantepidermalgrowthfactorreceptormutations AT hiranotoshiyuki characterizationoftheefficaciesofosimertinibandnazartinibagainstcellsexpressingclinicallyrelevantepidermalgrowthfactorreceptormutations AT kawadaichiro characterizationoftheefficaciesofosimertinibandnazartinibagainstcellsexpressingclinicallyrelevantepidermalgrowthfactorreceptormutations AT naokikatsuhiko characterizationoftheefficaciesofosimertinibandnazartinibagainstcellsexpressingclinicallyrelevantepidermalgrowthfactorreceptormutations AT soejimakenzo characterizationoftheefficaciesofosimertinibandnazartinibagainstcellsexpressingclinicallyrelevantepidermalgrowthfactorreceptormutations AT betsuyakutomoko characterizationoftheefficaciesofosimertinibandnazartinibagainstcellsexpressingclinicallyrelevantepidermalgrowthfactorreceptormutations |